MYGN prebiased their test by only including genes involved in cell cycle with the assumption that high levels of those genes indicates aggressive growth. If you look at their results, you will see that half of the men with aggressive disease are missed, IMO because the test does not look at alternative routes for disease progression.
In addition, the validation studies were biased towards white males due to the source of the validation material.
Market Data 
Markets 
AI
